Recent Patents on Anti-Cancer Drug Discovery
Title:Editorial (Thematic Issue: Modulation of Proteostasis and Proteolytic Pathways as an Anti-Cancer Strategy)
Volume: 12 Issue: 1
Author(s): David M. Pereira
Affiliation:
Export Options
About this article
Cite this article as:
Pereira M. David, Editorial (Thematic Issue: Modulation of Proteostasis and Proteolytic Pathways as an Anti-Cancer Strategy), Recent Patents on Anti-Cancer Drug Discovery 2017; 12 (1) . https://dx.doi.org/10.2174/157489281201170112201259
DOI https://dx.doi.org/10.2174/157489281201170112201259 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis
Current Clinical Pharmacology The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets PD-L1 Inhibitors for the Treatment of Prostate Cancer
Current Drug Targets Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors
Recent Patents on Anti-Cancer Drug Discovery Prevalence of Neuropathy Associated With Bortezomib: A Retrospective Study
Clinical Cancer Drugs Glutathione Peroxidase: A Potential Marker for the Most Common Diseases and Disorders
Recent Patents on Biomarkers In Vivo Optical Imaging in Gene & Cell Therapy
Current Gene Therapy Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot topic:Targeted Alpha Particle Therapy (Guest Editors: Ganesan Vaidyanathan and Roy Larsen)]
Current Radiopharmaceuticals Patent Selections:
Recent Patents on Nanotechnology Hydroxytyrosol and Derivatives: Isolation, Synthesis, and Biological Properties
Current Organic Chemistry Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Advantages of Nanotechnology- Based Chinese Herb Drugs on Biological Activities
Current Drug Metabolism Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology Small Molecule Inhibitors of p53/MDM2 Interaction
Current Topics in Medicinal Chemistry New Hybrids with 2-aminobenzothiazole and Azelayl Scaffolds: Synthesis, Molecular Docking and Biological Evaluation
Current Organic Chemistry Importance of Pharmacology Knowledge by Dieticians
Current Nutrition & Food Science DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer: Epigenetic Changes, Players in Transcriptional and Post- Transcriptional Regulation in Hereditary Breast Cancer
Current Molecular Medicine Targeted Regulation of PI3K/Akt/mTOR/NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry